Multiple myeloma has seen a deluge of new therapies and combination regimens in recent years aiming to extend progression-free survival and improve overall survival – and the flood is far from over.
Karyopharm Therapeutics Inc.'s selinexor may be the next novel agent to win US FDA approval, if the recent extension of the review period for its new drug application (NDA) gives the agency enough time and data to endorse the selective inhibitor of nuclear export (SINE) as a single agent for penta-refractory myeloma patients. (Also see "Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal" - Pink Sheet, 15 March, 2019
New Drugs, Combinations Come With High Prices
For perspectives on myeloma treatment cost concerns:
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?